Smoking Cessation and Nicotine De-Addiction Products Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
주요 인사이트
- 금연 및 니코틴 중독 치료 제품 시장 규모(2025년) : 83억 910만 달러
- 시장 규모 예측(2032년) : 163억 9,930만 달러
- 세계의 시장 성장률(2025-2032년) : CAGR 10.2%
시장 성장 촉진요인 :
세계의 금연 및 니코틴 중독 치료 제품 시장은 심혈관 질환, 암, 호흡기 질환 등 담배 사용으로 인한 건강 피해에 대한 전 세계적인 인식이 높아짐에 따라 성장세를 보이고 있습니다. 공공장소에서의 흡연 금지, 건강 위험에 대한 그래픽 경고 표시, 담배 제품에 대한 세금 부과와 같은 정부 규제는 소비자의 금연 의지를 강화하고 있습니다. 또한 니코틴 패치, 껌, 사탕, 바레니클린, 부프로피온과 같은 처방약 등 다양한 금연 제품을 쉽게 구할 수 있게 됨에 따라 개인별 맞춤형 치료 옵션이 확대되고 있습니다. 또한 행동 변화를 지원하는 디지털 헬스 플랫폼과 모바일 앱의 보급은 사용자의 참여와 치료 성공률을 높이는 요인으로 작용하고 있습니다.
시장 기회:
담배 규제 프로그램에 대한 정부의 투자 증가, 금연치료에 대한 보험 적용 확대, 중독 치료의 맞춤형 의료 발전으로 인해 시장은 유망한 기회를 보이고 있습니다. 가열식 담배, 개별화된 코칭 플랫폼, AI 기반 금연 지원 앱, 약리학적 개입과 행동요법을 결합한 병용요법 등 새로운 제품 포맷의 등장으로 치료의 방식이 크게 변화하고 있습니다. 제약사, 디지털 의료 제공자, 공중보건 기관 간의 전략적 파트너십을 구축함으로써 특히 지원이 닿기 어려운 지역에서의 혁신과 접근성 향상을 기대할 수 있습니다. 또한 직장내 건강 증진 프로그램 및 지역 사회에서의 인식 개선 활동은 제품 도입 및 인식 개선을 위한 새로운 플랫폼으로 주목받고 있습니다.
세계의 금연 및 니코틴 중독 치료 제품 시장을 조사했으며, 시장의 정의와 개요, 시장 성장 촉진요인·억제요인, 각종 동향, 시장 기회, 과제, 시장 규모 추이·예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 개요
제2장 시장 개요
- 시장의 범위와 정의
- 시장 역학
- 거시경제 요인
- COVID-19의 영향 분석
- 예측 요인 - 관련성과 영향
제3장 부가가치 인사이트
- 제품 채택 분석
- 질병 역학
- 기술의 진보
- 규제 상황
- 밸류체인 분석
- 제품의 USP 분석
- 주요 거래와 합병
- PESTLE 분석
- Porter's Five Forces 분석
제4장 가격 동향 분석
- 주요 하이라이트
- 제품 가격에 영향을 미치는 주요 요인
- 제품 유형별 가격 분석
- 지역 가격과 제품 선호도
제5장 세계의 금연 및 니코틴 중독 치료 제품 시장 전망
- 주요 하이라이트
- 시장 규모 분석·예측
- 세계의 금연 및 니코틴 중독 치료 제품 시장 전망 : 제품 유형별
- 세계의 금연 및 니코틴 중독 치료 제품 시장 전망 : 유통 채널별
- 서론/주요 조사 결과
- 과거 시장 규모 분석
- 현재 시장 규모 분석·예측
- 시장의 매력 분석
제6장 세계의 금연 및 니코틴 중독 치료 제품 시장 전망 : 지역별
- 주요 하이라이트
- 과거 시장 규모 분석 : 지역별
- 현재 시장 규모 분석·예측 : 지역별
- 북미
- 유럽
- 동아시아
- 남아시아와 오세아니아
- 라틴아메리카
- 중동 및 아프리카
- 시장의 매력 분석
제7장 북미의 금연 및 니코틴 중독 치료 제품 시장 전망
제8장 유럽의 금연 및 니코틴 중독 치료 제품 시장 전망
제9장 동아시아의 금연 및 니코틴 중독 치료 제품 시장 전망
제10장 남아시아 및 오세아니아의 금연 및 니코틴 중독 치료 제품 시장 전망
제11장 라틴아메리카의 금연 및 니코틴 중독 치료 제품 시장 전망
제12장 중동 및 아프리카의 금연 및 니코틴 중독 치료 제품 시장 전망
제13장 경쟁 구도
- 시장 점유율 분석
- 시장 구조
- 기업 개요(상세 - 개요, 재무, 전략, 최근 동향)
- Cipla
- Kenvue
- Pfizer Inc.
- Dr. Reddy's Laboratories Ltd.
- Aflofarm
- Fertin Pharma A/S
- Sopharma AD
- Perrigo Company plc,
- GSK Plc
- Rusan Pharma.
- British American Tobacco
- Sun Pharmaceutical Industries Ltd.
- GLENMARK PHARMACEUTICALS LTD.
- ITC Limited
- ZENIUS INDIA.
- Piramal Pharma Limited
- Swisher
- LUCY GOODS
- Mosaic Wellness PVT LTD.
- Saisir Global Technologies Pvt Ltd
- Lupin
- 기타
제14장 부록
KSA
Persistence Market Research has recently released a comprehensive report on the worldwide market for smoking cessation and nicotine de-addiction products. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global smoking cessation and nicotine de-addiction products market from 2025 to 2032.
Key Insights:
- Smoking Cessation and Nicotine De-Addiction Products Market Size (2025E): USD 8,309.1 Million
- Projected Market Value (2032F): USD 16,399.3 Million
- Global Market Growth Rate (CAGR 2025 to 2032): 10.2%
Smoking Cessation and Nicotine De-Addiction Products Market - Report Scope:
Smoking cessation and nicotine de-addiction products play a vital role in aiding individuals to overcome nicotine dependence, a major contributor to preventable diseases and premature mortality. These products, which include nicotine replacement therapies (NRTs), non-nicotine medications, e-cigarettes, and behavioral support tools, are used in medical settings, rehabilitation centers, and self-help programs to support tobacco users in quitting. The market serves a broad spectrum of users seeking structured de-addiction methods and is driven by growing awareness of smoking-related health risks, public health campaigns, and the implementation of strict tobacco control regulations.
Market Growth Drivers:
The global smoking cessation and nicotine de-addiction products market is driven by heightened global awareness of the health hazards associated with tobacco use, including cardiovascular disease, cancer, and respiratory conditions. Government regulations, such as bans on smoking in public spaces, graphic health warnings, and taxation on tobacco products, have bolstered consumer motivation to quit. The increasing availability of diverse cessation products-such as transdermal patches, nicotine gums, lozenges, and prescription medications like varenicline and bupropion-has expanded treatment options for individuals. Moreover, the rise of digital health platforms and mobile apps supporting behavior change enhances user engagement and therapy success rates.
Market Restraints:
Despite significant demand, the smoking cessation market faces barriers such as limited awareness of effective treatments in low- and middle-income countries, high costs associated with branded therapies, and social stigmas around seeking addiction treatment. Additionally, concerns regarding the safety and long-term effects of alternatives like e-cigarettes and vaping products have prompted regulatory scrutiny, leading to temporary bans or strict controls in several regions. The presence of unregulated products and misinformation about their efficacy or risks can further deter individuals from adopting evidence-based solutions, restricting overall market growth.
Market Opportunities:
The market presents promising opportunities due to increasing government investments in tobacco control programs, growing insurance coverage for cessation therapies, and advancements in personalized medicine for addiction treatment. Emerging product formats such as heat-not-burn devices, personalized coaching platforms, AI-driven quitting apps, and combination therapies integrating pharmacological and behavioral interventions are expected to transform the treatment landscape. Strategic partnerships between pharmaceutical companies, digital health providers, and public health institutions can also foster innovation and accessibility, especially in underserved regions. Additionally, workplace wellness programs and community outreach initiatives offer new platforms for product adoption and awareness.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the smoking cessation and nicotine de-addiction products market globally?
- Which product types and therapies are showing the highest adoption across regions?
- How are digital technologies and regulatory policies shaping the market landscape?
- Who are the leading companies in this market and what are their strategic growth initiatives?
- What are the future prospects and emerging trends in smoking cessation and nicotine de-addiction treatment?
Competitive Intelligence and Business Strategy:
Leading players in the global smoking cessation and nicotine de-addiction products market, including Mosaic Wellness PVT LTD., Aflofarm, Pfizer Inc., and Perrigo Company plc, are investing in research and development to improve product efficacy and user experience. These companies are expanding their product portfolios to include innovative delivery systems such as quick-dissolve strips and inhalers. Strategic mergers, acquisitions, and licensing agreements are being pursued to gain competitive advantages in regional markets. Moreover, partnerships with government agencies and health organizations support the delivery of cessation aids through subsidized or public health channels. Emphasis on digital integration, such as app-based therapy guidance and remote monitoring, is further transforming how cessation programs are delivered globally.
Key Companies Profiled:
- Cipla
- Kenvue
- Pfizer Inc.
- Dr. Reddy's Laboratories Ltd.
- Aflofarm
- Fertin Pharma A/S
- Sopharma AD
- Perrigo Company plc,
- GSK Plc
- Rusan Pharma.
- British American Tobacco
- Sun Pharmaceutical Industries Ltd.
- GLENMARK PHARMACEUTICALS LTD.
- ITC Limited
- ZENIUS INDIA.
- Piramal Pharma Limited
- Swisher
- LUCY GOODS
- Mosaic Wellness PVT LTD.
- Saisir Global Technologies Pvt Ltd
- Lupin
Market Segmentation
By Product Type
- Nicotine Replacement Therapy
- Lozenges
- Gums
- Sprays
- Inhalers
- patches
- Drug Therapy
- Varenicline-based Drugs
- Bupropion-based Drugs
- Cytisine-based Drugs
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Supermarkets/Hypermarkets
By Region
- North America
- Europe
- East Asia
- South Asia and Oceania
- Latin America
- Middle East and Africa
Table of Contents
1. Executive Summary
- 1.1. Global Smoking Cessation and Nicotine De-Addiction Products Market Snapshot, 2025-2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
- 2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.4. COVID-19 Impact Analysis
- 2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
- 3.1. Product Adoption Analysis
- 3.2. Disease Epidemiology
- 3.3. Technological Advancement
- 3.4. Regulatory Landscape
- 3.5. Value Chain Analysis
- 3.6. Product USP Analysis
- 3.7. Key Deals and Mergers
- 3.8. PESTLE Analysis
- 3.9. Porter's Five Force Analysis
4. Price Trend Analysis, 2019-2032
- 4.1. Key Highlights
- 4.2. Key Factors Impacting Product Prices
- 4.3. Pricing Analysis by Product Type
- 4.4. Regional Prices and Product Preferences
5. Global Smoking Cessation and Nicotine De-Addiction Products Market Outlook:
- 5.1. Key Highlights
- 5.1.1. Market Size (US$ Mn) and Y-o-Y Growth
- 5.1.2. Absolute $ Opportunity
- 5.2. Market Size (US$ Mn) Analysis and Forecast
- 5.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
- 5.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
- 5.3. Global Smoking Cessation and Nicotine De-Addiction Products Market Outlook: Product Type
- 5.3.1. Introduction / Key Findings
- 5.3.2. Historical Market Size (US$ Mn), By Product Type, 2019-2024
- 5.3.3. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
- 5.3.3.1. Nicotine Replacement Therapy
- 5.3.3.1.1. Lozenges
- 5.3.3.1.2. Gums
- 5.3.3.1.3. Sprays
- 5.3.3.1.4. Inhalers
- 5.3.3.1.5. Patches
- 5.3.3.2. Drug Therapy
- 5.3.3.2.1. Varenicline-based Drugs
- 5.3.3.2.2. Bupropion-based Drugs
- 5.3.3.2.3. Cytisine-based Drugs
- 5.3.4. Market Attractiveness Analysis: Product Type
- 5.4. Global Smoking Cessation and Nicotine De-Addiction Products Market Outlook: Distribution Channel
- 5.4.1. Introduction / Key Findings
- 5.4.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2024
- 5.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 5.4.3.1. Hospital Pharmacies
- 5.4.3.2. Retail Pharmacies
- 5.4.3.3. Online Pharmacies
- 5.4.3.4. Supermarkets/Hypermarkets
- 5.4.4. Market Attractiveness Analysis: Distribution Channel
6. Global Smoking Cessation and Nicotine De-Addiction Products Market Outlook: Region
- 6.1. Key Highlights
- 6.2. Historical Market Size (US$ Mn), By Region, 2019-2024
- 6.3. Current Market Size (US$ Mn) and Forecast, By Region, 2025-2032
- 6.3.1. North America
- 6.3.2. Europe
- 6.3.3. East Asia
- 6.3.4. South Asia and Oceania
- 6.3.5. Latin America
- 6.3.6. Middle East & Africa
- 6.4. Market Attractiveness Analysis: Region
7. North America Smoking Cessation and Nicotine De-Addiction Products Market Outlook:
- 7.1. Key Highlights
- 7.2. Historical Market Size (US$ Mn), By Market, 2019-2024
- 7.2.1. By Country
- 7.2.2. By Product Type
- 7.2.3. By Distribution Channel
- 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 7.3.1. U.S.
- 7.3.2. Canada
- 7.4. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
- 7.4.1. Nicotine Replacement Therapy
- 7.4.1.1. Lozenges
- 7.4.1.2. Gums
- 7.4.1.3. Sprays
- 7.4.1.4. Inhalers
- 7.4.1.5. patches
- 7.4.2. Drug Therapy
- 7.4.2.1. Varenicline-based Drugs
- 7.4.2.2. Bupropion-based Drugs
- 7.4.2.3. Cytisine-based Drugs
- 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 7.5.1. Hospital Pharmacies
- 7.5.2. Retail Pharmacies
- 7.5.3. Online Pharmacies
- 7.5.4. Supermarkets/Hypermarkets
- 7.6. Market Attractiveness Analysis
8. Europe Smoking Cessation and Nicotine De-Addiction Products Market Outlook:
- 8.1. Key Highlights
- 8.2. Historical Market Size (US$ Mn), By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Product Type
- 8.2.3. By Distribution Channel
- 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. Germany
- 8.3.2. France
- 8.3.3. U.K.
- 8.3.4. Italy
- 8.3.5. Spain
- 8.3.6. Russia
- 8.3.7. Turkey
- 8.3.8. Rest of Europe
- 8.4. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
- 8.4.1. Nicotine Replacement Therapy
- 8.4.1.1. Lozenges
- 8.4.1.2. Gums
- 8.4.1.3. Sprays
- 8.4.1.4. Inhalers
- 8.4.1.5. patches
- 8.4.2. Drug Therapy
- 8.4.2.1. Varenicline-based Drugs
- 8.4.2.2. Bupropion-based Drugs
- 8.4.2.3. Cytisine-based Drugs
- 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 8.5.1. Hospital Pharmacies
- 8.5.2. Retail Pharmacies
- 8.5.3. Online Pharmacies
- 8.5.4. Supermarkets/Hypermarkets
- 8.6. Market Attractiveness Analysis
9. East Asia Smoking Cessation and Nicotine De-Addiction Products Market Outlook:
- 9.1. Key Highlights
- 9.2. Historical Market Size (US$ Mn), By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Product Type
- 9.2.3. By Distribution Channel
- 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. South Korea
- 9.4. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
- 9.4.1. Nicotine Replacement Therapy
- 9.4.1.1. Lozenges
- 9.4.1.2. Gums
- 9.4.1.3. Sprays
- 9.4.1.4. Inhalers
- 9.4.1.5. patches
- 9.4.2. Drug Therapy
- 9.4.2.1. Varenicline-based Drugs
- 9.4.2.2. Bupropion-based Drugs
- 9.4.2.3. Cytisine-based Drugs
- 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 9.5.1. Hospital Pharmacies
- 9.5.2. Retail Pharmacies
- 9.5.3. Online Pharmacies
- 9.5.4. Supermarkets/Hypermarkets
- 9.6. Market Attractiveness Analysis
10. South Asia & Oceania Smoking Cessation and Nicotine De-Addiction Products Market Outlook:
- 10.1. Key Highlights
- 10.2. Historical Market Size (US$ Mn), By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Product Type
- 10.2.3. By Distribution Channel
- 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. India
- 10.3.2. Southeast Asia
- 10.3.3. ANZ
- 10.3.4. Rest of South Asia & Oceania
- 10.4. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
- 10.4.1. Nicotine Replacement Therapy
- 10.4.1.1. Lozenges
- 10.4.1.2. Gums
- 10.4.1.3. Sprays
- 10.4.1.4. Inhalers
- 10.4.1.5. patches
- 10.4.2. Drug Therapy
- 10.4.2.1. Varenicline-based Drugs
- 10.4.2.2. Bupropion-based Drugs
- 10.4.2.3. Cytisine-based Drugs
- 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 10.5.1. Hospital Pharmacies
- 10.5.2. Retail Pharmacies
- 10.5.3. Online Pharmacies
- 10.5.4. Supermarkets/Hypermarkets
- 10.6. Market Attractiveness Analysis
11. Latin America Smoking Cessation and Nicotine De-Addiction Products Market Outlook:
- 11.1. Key Highlights
- 11.2. Historical Market Size (US$ Mn), By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Product Type
- 11.2.3. By Distribution Channel
- 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 11.3.1. Brazil
- 11.3.2. Mexico
- 11.3.3. Rest of Latin America
- 11.4. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
- 11.4.1. Nicotine Replacement Therapy
- 11.4.1.1. Lozenges
- 11.4.1.2. Gums
- 11.4.1.3. Sprays
- 11.4.1.4. Inhalers
- 11.4.1.5. patches
- 11.4.2. Drug Therapy
- 11.4.2.1. Varenicline-based Drugs
- 11.4.2.2. Bupropion-based Drugs
- 11.4.2.3. Cytisine-based Drugs
- 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 11.5.1. Hospital Pharmacies
- 11.5.2. Retail Pharmacies
- 11.5.3. Online Pharmacies
- 11.5.4. Supermarkets/Hypermarkets
- 11.6. Market Attractiveness Analysis
12. Middle East & Africa Smoking Cessation and Nicotine De-Addiction Products Market Outlook:
- 12.1. Key Highlights
- 12.2. Historical Market Size (US$ Mn), By Market, 2019-2024
- 12.2.1. By Country
- 12.2.2. By Product Type
- 12.2.3. By Distribution Channel
- 12.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 12.3.1. GCC Countries
- 12.3.2. Egypt
- 12.3.3. South Africa
- 12.3.4. Northern Africa
- 12.3.5. Rest of Middle East & Africa
- 12.4. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
- 12.4.1. Nicotine Replacement Therapy
- 12.4.1.1. Lozenges
- 12.4.1.2. Gums
- 12.4.1.3. Sprays
- 12.4.1.4. Inhalers
- 12.4.1.5. patches
- 12.4.2. Drug Therapy
- 12.4.2.1. Varenicline-based Drugs
- 12.4.2.2. Bupropion-based Drugs
- 12.4.2.3. Cytisine-based Drugs
- 12.5. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 12.5.1. Hospital Pharmacies
- 12.5.2. Retail Pharmacies
- 12.5.3. Online Pharmacies
- 12.5.4. Supermarkets/Hypermarkets
- 12.6. Market Attractiveness Analysis
13. Competition Landscape
- 13.1. Market Share Analysis, 2025
- 13.2. Market Structure
- 13.2.1. Competition Intensity Mapping by Market
- 13.2.2. Competition Dashboard
- 13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 13.3.1. Cipla
- 13.3.1.1. Overview
- 13.3.1.2. Segments and Product
- 13.3.1.3. Key Financials
- 13.3.1.4. Market Developments
- 13.3.1.5. Market Strategy
- 13.3.2. Kenvue
- 13.3.3. Pfizer Inc.
- 13.3.4. Dr. Reddy's Laboratories Ltd.
- 13.3.5. Aflofarm
- 13.3.6. Fertin Pharma A/S
- 13.3.7. Sopharma AD
- 13.3.8. Perrigo Company plc,
- 13.3.9. GSK Plc
- 13.3.10. Rusan Pharma.
- 13.3.11. British American Tobacco
- 13.3.12. Sun Pharmaceutical Industries Ltd.
- 13.3.13. GLENMARK PHARMACEUTICALS LTD.
- 13.3.14. ITC Limited
- 13.3.15. ZENIUS INDIA.
- 13.3.16. Piramal Pharma Limited
- 13.3.17. Swisher
- 13.3.18. LUCY GOODS
- 13.3.19. Mosaic Wellness PVT LTD.
- 13.3.20. Saisir Global Technologies Pvt Ltd
- 13.3.21. Lupin
- 13.3.22. Others
14. Appendix
- 14.1. Research Methodology
- 14.2. Research Assumptions
- 14.3. Acronyms and Abbreviations
